MITOXANTRONE-DNA BINDING AND THE INDUCTION OF TOPOISOMERASE-II ASSOCIATED DNA DAMAGE IN MULTIDRUG RESISTANT SMALL-CELL LUNG-CANCER CELLS

被引:69
作者
SMITH, PJ
MORGAN, SA
FOX, ME
WATSON, JV
机构
[1] MRC Clinical Oncology and Radiotherapeutics Unit, MRC Centre, Cambridge
关键词
D O I
10.1016/0006-2952(90)90237-F
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The cytotoxicity anti-tumour intercalating agents such as the anthraquinone mitoxantrone is thought to relate to DNA binding and the trapping of DNA topoisomerase II complexes on cellular DNA. We have studied the uptake, nuclear location, DNA binding mode and DNA damaging capacity of mitoxantrone in a small cell lung carcinoma cell line (NCI-H69) compared with an in vitro-derived variant subline (NCI-H69/LX4) that exhibits "classical" multi-drug resistance (MDR). Variant cells maintained under doxorubicin selection showed reduced RNA levels that returned to control values within 7 days of growth under non-selective conditions. Variant cells released from selection stress showed resistance to DNA cleavage by doxorubicin, mitoxantrone, 4'-epidoxorubicin, 4'-deoxy-doxorubicin but reduced resistance to aclacinomycin A and a 9-alkyl substituted anthracycline in broad agreement with the cross-resistance patterns for cytotoxicity. Mitoxantrone treated NCI-H69 cells were found to accumulate DNA-protein crosslinks during a 4hr post-treatment incubation period whereas variant cells maintained depressed levels of crosslinking. There was no apparent abnormality in the availability or drug sensitivity of topoisomerase II assayed in crude nuclear extracts of NCI-H69/LX4 cells. Whole cell uptake of radiolabelled mitoxantrone was depressed (50%) in NCI-H69/LX4 compared with NCI-H69, whereas assessment of nuclear-bound drug in individual cells by a fluorescence quenching technique showed at least a 10-fold greater level of target protection. The quenching results provide evidence of a high affinity, saturable mode of drug binding, favoured at low drug concentrations, that correlated with DNA cleavage capacity. We propose that the cytotoxic action of mitoxantrone is dependent upon a restricted and persistent form of binding to DNA that favours the long-term or progressive trapping of topoisomerase II complexes. © 1990.
引用
收藏
页码:2069 / 2078
页数:10
相关论文
共 36 条
[1]  
ALBERTS DS, 1985, INVEST NEW DRUG, V3, P101
[2]  
ARUNDEL CM, 1988, CANCER RES, V48, P5669
[3]   SELECTIVE DISPLACEMENT OF NUCLEAR PROTEINS BY ANTITUMOR DRUGS HAVING AFFINITY FOR NUCLEIC-ACIDS [J].
BARTKOWIAK, J ;
KAPUSCINSKI, J ;
MELAMED, MR ;
DARZYNKIEWICZ, Z .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (13) :5151-5154
[4]  
BASRA J, 1985, ANTI-CANCER DRUG DES, V1, P42
[5]   PHYSICOCHEMICAL STUDY OF COMPLEXES OF 33258-HOECHST WITH DNA AND NUCLEOHISTONE [J].
BONTEMPS, J ;
HOUSSIER, C ;
FREDERICQ, E .
NUCLEIC ACIDS RESEARCH, 1975, 2 (06) :971-984
[6]  
BOWDEN GT, 1985, CANCER RES, V45, P4915
[7]   IDENTIFICATION OF ANTHRACYCLINES AND RELATED AGENTS THAT RETAIN PREFERENTIAL ACTIVITY OVER ADRIAMYCIN IN MULTIDRUG-RESISTANT CELL-LINES, AND FURTHER RESISTANCE MODIFICATION BY VERAPAMIL AND CYCLOSPORINE-A [J].
COLEY, HM ;
TWENTYMAN, PR ;
WORKMAN, P .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1989, 24 (05) :284-290
[8]   IMPROVED CELLULAR ACCUMULATION IS CHARACTERISTIC OF ANTHRACYCLINES WHICH RETAIN HIGH-ACTIVITY IN MULTIDRUG RESISTANT CELL-LINES, ALONE OR IN COMBINATION WITH VERAPAMIL OR CYCLOSPORINE-A [J].
COLEY, HM ;
TWENTYMAN, PR ;
WORKMAN, P .
BIOCHEMICAL PHARMACOLOGY, 1989, 38 (24) :4467-4475
[9]  
DENNY WA, 1989, ANTI-CANCER DRUG DES, V4, P241
[10]   THE BIOCHEMISTRY OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCE [J].
ENDICOTT, JA ;
LING, V .
ANNUAL REVIEW OF BIOCHEMISTRY, 1989, 58 :137-171